Olanzapine
Drugolanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
NCT Number: NCT03118986
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
Interested in participating?
Request Info30 month–18 year
All sexes
Interventional
Phase 2
Cancer Care Manitoba, Winnipeg, Manitoba, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Planned receipt of HEC or cyclophosphamide ≥ 1 g/m2/day (≥ 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg/m²/dose, cisplatin ≥12mg/m²/dose, cytarabine ≥3g/m²/day, melphalan >140mg/m², methotrexate ≥12g/m²/dose and thiotepa ≥300mg/m²/dose.
Plan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.
Body weight of at least 12.5 kg
2.5 to < 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.
Samples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:
Baseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc
A plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.
Negative pregnancy test if female of childbearing potential
Patients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence
Parent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.
Optional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent/guardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent/guardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.
olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
Time frame: up to 8 days
Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase
Time frame: up to 8 days
Partial control is defined as no more than two vomits or retches during any 24-hr period
Time frame: up to 1 month
Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period
Time frame: up to 1 month
Based on descriptive statistics on reported toxicities.
Time frame: up to 1 month
Based on descriptive statistics on reported body weight
Time frame: up to 1 month
Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.
Time frame: up to 1 month
Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms
Time frame: up to 1 month
Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms
Time frame: up to 1 month
Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms
Time frame: up to 1 month
Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms
Time frame: From first HSCT conditioning dose until 100 days post-HSCT
Looking at incidence of veno-occlusive disease
Time frame: From first HSCT conditioning dose until 100 days post-HSCT
Looking at incidence of GVHD between the two arms
Time frame: From first HSCT conditioning dose until 100 days post-HSCT
Comparing the incidence of the different maximal grades of GVHD between the two arms
Time frame: up to 1 month
taking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT
Contact information is provided by the study sponsor or research team.
The Hospital for Sick Children
Other
Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07280624
Abdominal Pain, Abdominal Pain/ Discomfort
View Trial DetailsNCT05076461
Acute Gastroenteritis, Vomiting in Infants and/or Children
Liaquatpur, Punjab Province, Pakistan
View Trial DetailsNCT07169851
Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions
Greenbrae, California, United States
View Trial DetailsNCT01440465
Cancer, Nausea
Avranches, France
View Trial Details